Product NDC: | 63323-105 |
Proprietary Name: | Acyclovir |
Non Proprietary Name: | ACYCLOVIR SODIUM |
Active Ingredient(s): | 50 mg/mL & nbsp; ACYCLOVIR SODIUM |
Administration Route(s): | INTRAVENOUS |
Dosage Form(s): | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 63323-105 |
Labeler Name: | APP Pharmaceuticals, LLC |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA075015 |
Marketing Category: | ANDA |
Start Marketing Date: | 20001017 |
Package NDC: | 63323-105-10 |
Package Description: | 10 VIAL in 1 TRAY (63323-105-10) > 10 mL in 1 VIAL |
NDC Code | 63323-105-10 |
Proprietary Name | Acyclovir |
Package Description | 10 VIAL in 1 TRAY (63323-105-10) > 10 mL in 1 VIAL |
Product NDC | 63323-105 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | ACYCLOVIR SODIUM |
Dosage Form Name | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
Route Name | INTRAVENOUS |
Start Marketing Date | 20001017 |
Marketing Category Name | ANDA |
Labeler Name | APP Pharmaceuticals, LLC |
Substance Name | ACYCLOVIR SODIUM |
Strength Number | 50 |
Strength Unit | mg/mL |
Pharmaceutical Classes | DNA Polymerase Inhibitors [MoA],Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC],Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC],Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient] |